These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia: further evidence for disease course-related immune alterations? Busse S; Busse M; Schiltz K; Bielau H; Gos T; Brisch R; Mawrin C; Schmitt A; Jordan W; Müller UJ; Bernstein HG; Bogerts B; Steiner J Brain Behav Immun; 2012 Nov; 26(8):1273-9. PubMed ID: 22917959 [TBL] [Abstract][Full Text] [Related]
4. [The relationship between inflammation, cognitive disorders and neuroimaging data in schizophrenia]. Ushakov VL; Malashenkova IK; Kostyuk GP; Zakharova NV; Krynskiy SA; Kartashov SI; Ogurtsov DP; Bravve LV; Kaydan MA; Hailov NA; Chekulaeva EI; Didkovsky NA Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(11):70-78. PubMed ID: 33340301 [TBL] [Abstract][Full Text] [Related]
5. Construction of a Neuro-Immune-Cognitive Pathway-Phenotype Underpinning the Phenome of Deficit Schizophrenia. Al-Hakeim HK; Almulla AF; Al-Dujaili AH; Maes M Curr Top Med Chem; 2020; 20(9):747-758. PubMed ID: 31994463 [TBL] [Abstract][Full Text] [Related]
6. [Immunological marker activity in first episode schizophrenic patients]. Szulc A; Galińska B; Konarzewska B; Gudel-Trochimowicz I; Popławska R Pol Merkur Lekarski; 2001 Jun; 10(60):450-2. PubMed ID: 11503261 [TBL] [Abstract][Full Text] [Related]
7. Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Wilke I; Arolt V; Rothermundt M; Weitzsch C; Hornberg M; Kirchner H Eur Arch Psychiatry Clin Neurosci; 1996; 246(5):279-84. PubMed ID: 8863007 [TBL] [Abstract][Full Text] [Related]
8. Acute phase proteins as biological markers of negative psychopathology in paranoid schizophrenia. Morera AL; Henry M; García-Hernández A; Fernández-López L Actas Esp Psiquiatr; 2007; 35(4):249-52. PubMed ID: 17592787 [TBL] [Abstract][Full Text] [Related]
9. [The P 300 potential in schizophrenia]. Laurent A; Garcia-Larrea L; Dalery J; Terra JL; D'Amato T; Marie-Cardine M; Mauguière F Encephale; 1993; 19(3):221-7. PubMed ID: 8275907 [TBL] [Abstract][Full Text] [Related]
10. Do neurobiological differences exist between paranoid and non-paranoid schizophrenia? Findings from the bipolar schizophrenia network on intermediate phenotypes study. Lutz O; Lizano P; Mothi SS; Zeng V; Hegde RR; Hoang DT; Henson P; Brady R; Tamminga CA; Pearlson G; Clementz BA; Sweeney JA; Keshavan MS Schizophr Res; 2020 Sep; 223():96-104. PubMed ID: 32507376 [TBL] [Abstract][Full Text] [Related]
11. [Features of the immune profile of schizophrenic patients with catatonic syndrome]. Zakharova NV; Zozulya SA; Sarmanova ZV; Bravve LV; Otman IN; Klyushnik TP Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(6. Vyp. 2):46-53. PubMed ID: 32729690 [TBL] [Abstract][Full Text] [Related]
12. [Glutamate receptors genes polymorphism and the risk of paranoid schizophrenia in Russians and tatars from the Republic of Bashkortostan]. Gareeva AE; Khusnutdinova EK Mol Biol (Mosk); 2014; 48(5):771-81. PubMed ID: 25842862 [TBL] [Abstract][Full Text] [Related]
13. PECULIARITIES OF BRAIN-DERIVED NEUROTROPHIC FACTOR AND MATRIX METALLOPROTEINASE-9 EXPRESSION DYNAMICS IN PATIENTS WITH PARANOID SCHIZOPHRENIA DEPENDING ON THE DURATION OF THE DISEASE. Romash IR; Vynnyk MI Wiad Lek; 2021; 74(11 cz 1):2728-2732. PubMed ID: 35023483 [TBL] [Abstract][Full Text] [Related]
14. Paranoid schizophrenia: an unorthodox view. Zigler E; Glick M Am J Orthopsychiatry; 1984 Jan; 54(1):43-70. PubMed ID: 6703023 [TBL] [Abstract][Full Text] [Related]
15. Gut microbiome and adaptive immunity in schizophrenia. Agorastos A; Bozikas VP Psychiatriki; 2019; 30(3):189-192. PubMed ID: 31685450 [TBL] [Abstract][Full Text] [Related]
16. [Depression in the structure of schizophrenia: clinical and biochemical characteristics]. Petrova NN; Tsyrenova KA; Dorofeikova MV Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(5. Vyp. 2):84-90. PubMed ID: 34405662 [TBL] [Abstract][Full Text] [Related]
17. A Cross-Sectional Study on Associations Between BDNF, CRP, IL-6 and Clinical Symptoms, Cognitive and Personal Performance in Patients With Paranoid Schizophrenia. Chumakov E; Dorofeikova M; Tsyrenova K; Petrova N Front Psychiatry; 2022; 13():943869. PubMed ID: 35873262 [TBL] [Abstract][Full Text] [Related]
18. Association of baseline inflammatory markers and the development of negative symptoms in individuals at clinical high risk for psychosis. Goldsmith DR; Haroon E; Miller AH; Addington J; Bearden C; Cadenhead K; Cannon T; Cornblatt B; Mathalon D; McGlashan T; Seidman L; Tsuang M; Woods SW; Walker EF; Perkins DO Brain Behav Immun; 2019 Feb; 76():268-274. PubMed ID: 30496778 [TBL] [Abstract][Full Text] [Related]
19. [Symptoms of paranoid schizophrenia and anxiety: a dynamic analysis]. Spila B; Karakuła H; Grzywa A Psychiatr Pol; 2001; 35(6):937-49. PubMed ID: 11877888 [TBL] [Abstract][Full Text] [Related]
20. Investigation of serum cytokine levels and cytokine production in whole blood cultures of paranoid schizophrenic patients. Kamińska T; Wysocka A; Marmurowska-Michalowska H; Dubas-Slemp H; Kandefer-Szerszeń M Arch Immunol Ther Exp (Warsz); 2001; 49(6):439-45. PubMed ID: 11814238 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]